The medical device sector has long been a highly profitable area for investors. As the industry has matured and become more competitive, however, investors have had to be more careful when selecting stocks in this high-growth industry.
The medical device market is composed of companies that produce equipment used for diagnosing, treating, and monitoring medical conditions. This market is undergoing significant change.
Beyond 2022, the escalating prevalence and incidence of chronic diseases will have a substantial impact on the global medical device market. This promotes the use of ever-improving technology tools for early disease detection as well as the development of intelligent equipment such as 3D printing, robots, and the internet of things.
Consequently, the market for medical device technology will increase at a CAGR of 4.9% between 2022 and 2027. Predictions call for a rise from
In this article, we will examine a few medical device stocks to put on your watchlist.
The iHelpMAX and its platform can be linked to a number of other devices so that vital signs can be monitored remotely and collected in real time. This remote monitoring enables telehealth capabilities for the unit, a feature that will set WHSI up for success in the ever-changing medical device market.
According to
WHSI reported serving 8,500 end users of their PERS device, the iHelpMAX 4G, as of
Analyst
In a lawsuit filed against
The company's current product lines include its Prizma medical device, a clinical-grade device that can transform nearly any smartphone into a medical monitoring device, allowing healthcare providers and individuals to monitor, manage, and share a wide range of vital signs and biometric indicators.
Last week, GMVD announced that it received two granted patents from the United States Patent and
One patent includes a sensing mechanism that enables the monitoring system to analyze sensing conditions, such as pressure, ambient temperature, light, conductivity, etc., prior to and during continuous monitoring of physiological signals from the body. This allows for greater and more precise sensing, which reduces false positive readings, including false alarms.
The second patent converts the concept of the conventional smartphone flip case into a medical case, enabling consumers and patients to carry their smartphones and monitoring device at the same time, thereby ensuring the ability to monitor vital signs and other parameters.
They distinguish themselves by empowering consumers to purchase hearing aids online, at retail locations, or over the phone, and by providing convenient consultation and support from hearing professionals via phone, text, email, and video chat.
People can buy
EAR just said that
Patient Square now owns about 76.3% of
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, assumptions of future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degrees of risk. It is possible that an investors investment may be lost or due to the speculative nature of of the companies profiled. CaptalGainsReport 'CGR' is responsible for the production and distributions of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. CGR authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. CGR is compensated
Media Contact
Company
Contact Person:
Email: mark@capitalgainsreport.com
City:
State:
Country:
Website: https://capitalgainsreport.com/
Source: www.abnewswire.com
.
(C) 2022 M2 COMMUNICATIONS, source